Search | Clinical Trials Finder

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tofimilast; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 23
States / cities: Phoenix, Arizona • Riverside, California • Clearwater, Florida + 18 more

Conditions: General Skin Cleansing
Interventions: Chlorhexidine Gluconate, HUBS with Hibiclens; Drug · Combination Product
Lead sponsor: Caroline Scott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Migraine
Interventions: ASY202, Placebo; Combination Product
Lead sponsor: Aspeya, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Walnut Creek, California • Orlando, Florida • Las Vegas, Nevada + 2 more

Conditions: COVID-19
Interventions: ALG-097558, Dabigatran, Itraconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cervical Radiculopathy, Myelopathy
Interventions: Anterior Cervical Discectomy and Fusion; Procedure
Lead sponsor: LifeNet Health; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Ridge Preservation, Allografts, Extraction, Tooth, Xenograft
Interventions: FDBA, CEBX; Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Dry Eye
Interventions: DE-110 ophthalmic suspension high dose, DE-110 ophthalmic suspension low dose, Placebo; Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Inglewood, California • Newport Beach, California • Petaluma, California + 11 more

Conditions: Treatment of Dry Eye Disease
Interventions: Restasis, Refresh Plus; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: 6400 Fannin Ste 1800, Texas

Conditions: Genitourinary Syndrome of Menopause
Interventions: StrataMGT, Estrace 0.01% Vaginal Cream; Device · Drug
Lead sponsor: Stratpharma AG; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Laguna Hills, California • Miami, Florida • Johns Creek, Georgia

Conditions: Age-Related Macular Degeneration
Interventions: MA09-hRPE; Biological
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 55 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Dry Eye Disease (DED)
Interventions: NOV03, Placebo; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 11
States / cities: Artesia, California • Newport Beach, California • Santa Ana, California + 6 more

Conditions: HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B); Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Dry Eye Disease
Interventions: Loteprednol etabonate, Artificial Tears, Restasis; Drug
Lead sponsor: Edward Holland, MD; Other
Eligibility: 21 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Edgewood, Kentucky

Conditions: Caries,Dental
Interventions: LumiCare rinse, QLF Inspektor Pro Imaging; Device
Lead sponsor: Tufts University; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amputation Stumps, Neuroma
Interventions: Bupivacaine, Placebo; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Open Wound, Wound Heal
Interventions: Micro/nanobubble (MNB) - Irrigation, 0.9% Normal Saline - Irrigation, Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi), 0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi); Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Ovarian Cancer
Interventions: Fermented Wheat Germ Extract (FWGE), Placebo, Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Dengue
Interventions: Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Sjogren's Syndrome, Xerostomia
Interventions: Thalidomide; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Arterial Hypertension
Interventions: Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI); Combination Product
Lead sponsor: Respira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more

Conditions: Dry Eye Disease (DED)
Interventions: 3% trehalose; Drug
Lead sponsor: Southern California College of Optometry at Marshall B. Ketchum University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Age Related Macular Degeneration (AMD)
Interventions: GT005; Genetic
Lead sponsor: Gyroscope Therapeutics Limited; Industry
Eligibility: 55 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 22
States / cities: Poway, California • Durango, Colorado • Gainesville, Florida + 18 more

Conditions: Efficacy, Safety Issues
Interventions: AMIA with SHARESOURCE Connectivity Platform, HomeChoice PRO; Combination Product · Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Chula Vista, California • San Diego, California

Conditions: Age-related Memory Disorders, Mood Disorders
Interventions: Omega-3 fatty acid, Blueberry powder, Placebo oil, Placebo powder; Dietary Supplement · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 62 Years to 80 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease

Removal of Bacterial Spores in Adults on Skin

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

Safety Study of Preservon-Treated Bone Implants for Cervical Fusion in the Treatment of Cervical Radiculopathy or Myelopathy

Comparison of Two Types of Bone Grafts in Patients Who Need One of Their Front Teeth Removed and Replaced With an Implant

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease

Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

Caries Detection With Two Different Caries Detecting Devices

Pathophysiology of Post Amputation Pain

Micro/Nanobubbles (MNBs) for Treatment of Acute and Chronic Wounds

Fermented Wheat Germ Extract in Women With Ovarian Cancer

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

Pilot Study of Thalidomide to Treat Sjogren's Syndrome

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline